Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate - PubMed (original) (raw)
Clinical Trial
. 2002 Jul 15;20(14):3072-80.
doi: 10.1200/JCO.2002.12.065.
Affiliations
- PMID: 12118020
- DOI: 10.1200/JCO.2002.12.065
Clinical Trial
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
Christos N Papandreou et al. J Clin Oncol. 2002.
Abstract
Purpose: To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa.
Patients and methods: Patients with SCPCa (pure or mixed), measurable disease, good organ function, and no prior treatment with doxorubicin, etoposide, or cisplatin were treated every 4 weeks with doxorubicin 50 mg/m(2) as a 24-hour intravenous (IV) infusion followed by etoposide 120 mg/m(2)/d and cisplatin 25 mg/m(2)/d IV on days 2 to 4.
Results: Thirty-eight patients (36 assessable for response) were treated for a median of four cycles. Twenty-nine (81%) of 36 patients had prior hormonal therapy. Study patients had visceral metastases, lytic bone disease, and relatively low serum prostate-specific antigen (PSA). We observed 22 partial responses (response rate, 61% in an intent-to-treat analysis); toxicity was severe (grade 3 or 4 neutropenia 100%, thrombocytopenia 66%, mucositis 21%, and infection 68%). Three patients died of toxicity. Median time to progression and overall survival time were 5.8 months and 10.5 months, respectively. Performance status, serum albumin, and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) were predictors of survival.
Conclusion: SCPCa presents unique clinicopathologic features. Addition of doxorubicin to the etoposide/cisplatin regimen caused higher toxicity in this patient population and failed to improve outcome. Given these results, we do not recommend further development of this regimen for patients with SCPCa. Improvement in therapy will come from understanding the biology of SCPCa progression and integrating new targeted therapies into the treatment of SCPCa.
Similar articles
- Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ Jr, Movsas B, Byhardt RW; Radiation Therapy Oncology Group 9609. Ettinger DS, et al. J Clin Oncol. 2005 Aug 1;23(22):4991-8. doi: 10.1200/JCO.2005.00.414. Epub 2005 Jun 6. J Clin Oncol. 2005. PMID: 15939930 Clinical Trial. - A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M. Tabata M, et al. Cancer Chemother Pharmacol. 2007 Jun;60(1):1-6. doi: 10.1007/s00280-006-0336-0. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2007. PMID: 17393168 Clinical Trial. - Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC. Johnson BE, et al. J Clin Oncol. 1996 Mar;14(3):806-13. doi: 10.1200/JCO.1996.14.3.806. J Clin Oncol. 1996. PMID: 8622028 Clinical Trial. - A case of small cell carcinoma of the prostate and review of the literature.
Addeo A, Rinaldi C, Panades M. Addeo A, et al. Tumori. 2012 May-Jun;98(3):76e-78e. doi: 10.1700/1125.12415. Tumori. 2012. PMID: 22825523 Review. - Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature.
Sharma D, Flora G, Grunberg SM. Sharma D, et al. Am J Clin Oncol. 1991 Apr;14(2):166-9. doi: 10.1097/00000421-199104000-00014. Am J Clin Oncol. 1991. PMID: 2028925 Review.
Cited by
- Prognostic nomogram to predict cancer-specific survival with small-cell carcinoma of the prostate: a multi-institutional study.
Di Y, Song J, Song Z, Wang Y, Meng L. Di Y, et al. Front Oncol. 2024 May 10;14:1349888. doi: 10.3389/fonc.2024.1349888. eCollection 2024. Front Oncol. 2024. PMID: 38800400 Free PMC article. - Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.
Zheng D, Zhang Y, Yang S, Su N, Bakhoum M, Zhang G, Naderinezhad S, Mao Z, Wang Z, Zhou T, Li W. Zheng D, et al. Cell Death Discov. 2024 May 22;10(1):246. doi: 10.1038/s41420-024-02031-1. Cell Death Discov. 2024. PMID: 38777812 Free PMC article. - Acute sensorimotor paraneoplastic neuropathy in a patient with small cell prostate cancer.
Faggin M, McCann B, Gallagher P, Salmond J. Faggin M, et al. BMJ Case Rep. 2024 Feb 27;17(2):e258380. doi: 10.1136/bcr-2023-258380. BMJ Case Rep. 2024. PMID: 38417933 - A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga - DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT).
Kumar A, Prakash A, Kumar Upadhyay A, Kumar B, Mitra S. Kumar A, et al. Cureus. 2024 Jan 16;16(1):e52375. doi: 10.7759/cureus.52375. eCollection 2024 Jan. Cureus. 2024. PMID: 38361734 Free PMC article. - Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.
Baude J, Niogret J, Jacob P, Bardet F, Desmoulins I, Zanetta S, Kaderbhai C, Galland L, Mayeur D, Delattre B, Cormier L, Ladoire S. Baude J, et al. Cancers (Basel). 2024 Jan 9;16(2):280. doi: 10.3390/cancers16020280. Cancers (Basel). 2024. PMID: 38254771 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous